Sex Differences in Substance Use and Misuse: A Toxicology Investigators\u27 Consortium (ToxIC) Registry Analysis by Beauchamp, Gillian A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2020-09-29 
Sex Differences in Substance Use and Misuse: A Toxicology 
Investigators' Consortium (ToxIC) Registry Analysis 
Gillian A. Beauchamp 
University of South Florida 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Gender and Sexuality Commons, Medical Toxicology Commons, Substance Abuse and 
Addiction Commons, and the Toxicology Commons 
Repository Citation 
Beauchamp GA, Carey JL, Hurwitz MB, Tully BN, Cook MD, Cannon RD, Katz KD, Koons AL, Kincaid H, 
Greenberg MR. (2020). Sex Differences in Substance Use and Misuse: A Toxicology Investigators' 
Consortium (ToxIC) Registry Analysis. University of Massachusetts Medical School Faculty Publications. 
https://doi.org/10.2147/SAR.S263165. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/
1944 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
O R I G I N A L  R E S E A R C H
Sex Differences in Substance Use and Misuse: 
A Toxicology Investigators’ Consortium (ToxIC) 
Registry Analysis
This article was published in the following Dove Press journal: 
Substance Abuse and Rehabilitation
Gillian A Beauchamp1,2 
Jennifer L Carey 3 
Mikayla B Hurwitz1 
Briana N Tully1 
Matthew D Cook1,2 
Robert D Cannon1,2 
Kenneth D Katz1,2 
Andrew L Koons1,2 
Hope Kincaid4 
Marna Rayl Greenberg 1  
On Behalf of the Toxicology 
Investigators Consortium 
(ToxIC)
1Department of Emergency and Hospital 
Medicine, Lehigh Valley Health Network/ 
University of South Florida (USF) Morsani 
College of Medicine, Allentown, PA 
18103, USA; 2Section of Medical 
Toxicology, Department of Emergency 
and Hospital Medicine, Lehigh Valley 
Health Network/USF Morsani College of 
Medicine, Allentown, PA 18103, USA; 
3Division of Medical Toxicology, 
Department of Emergency Medicine, 
University of Massachusetts Medical 
School, Worcester, MA 01655, USA; 
4Network Office of Research and 
Innovation, Lehigh Valley Health 
Network/USF Morsani College of 
Medicine, Allentown, PA 18103, USA 
Background: Variations between male and female populations are previously reported in 
classes of harmfully used/misused drugs, severity of substance use disorder and risk of 
relapse. The aim of this study was to provide a review of bedside medical toxicologist 
managed, sex-specific poisonings in adults that present with harmful drug use/misuse.
Methods: ToxIC Registry cases ≥19 and ≤65 years old, with harmful drug use or misuse 
during the timeframe June 2010–December 2016, were studied. Demographics, primary 
agents of toxic exposure, administration route and complications were analyzed. 
Descriptive methods were used in the analysis.
Results: The database included 51,440 cases. Of these, 3426 cases were analyzed in which the 
primary reason for the encounter was harmful substance use/misuse. Females were found to 
harmfully use/misuse pharmaceutical drugs (N=806, 65.6%) more than nonpharmaceutical 
drugs (N=423, 34.4%). Males more frequently used nonpharmaceutical drugs (N=1189, 
54.1%) than pharmaceutical drugs (1008, 45.9%). Analgesics were used by females (N= 215, 
18.2%) and males (N=137, 6.6%). Sedative hypnotics were used by females (N=165, 14%) and 
males (N=160, 7.8%). Psychoactive agents were used by males (N=325, 15.8%) and females 
(N=67, 5.7%). Sympathomimetics were used by males (N=381, 18.5%) and females (N=151, 
12.8%). The majority of both male and female participants, 1712 (57.9%), utilized an oral route 
of administration. However, 312 (16.5%) of males utilized inhalation vs 73 (6.8%) of females 
inhaled their substance.
Conclusion: There were sex-specific differences among patients evaluated for harmful 
substance use/misuse by toxicologists. Considering these differences in regards to manage-
ment and preventive approaches may be indicated.
Keywords: gender studies, substance use, toxicology, overdose, substance misuse
Introduction
Harmful use of substances is an ongoing worldwide problem. Prior research has 
found that many risk factors contribute to harmful substance use and overdose.1 
There are many factors that contribute to the risk of overdose, such as intravenous 
administration, poly-drug use, drug impurity, and even brief abstinence preceding 
exposure.1 Due to the complexities that contribute to harmful substance use, the 
CDC continues to recommend research and development into strategies to mitigate 
risk for those vulnerable to overdose by identifying what substance use profiles to 
anticipate from an individual.1 Previous research has found a variety of sex-based 
differences around harmful substance use.2 In a study looking at people who filled 
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an opioid prescription, the authors found that women 
received lower opioid doses than men, but were more 
likely to have antidepressant, benzodiazepine, or zolpidem 
prescriptions.3 Becker et al also found that women began 
self-administering illicit and licit drugs at lower doses, but 
experience a quicker increase in their addiction to these 
drugs, as well as a higher difficulty of cessation.4,5 
Another study found that women reported more prescrip-
tion opioid use in their lifetime than men.6 Graziani et al 
specifically studied oxycodone and hydrocodone and 
found that, although the pharmacokinetic and pharmaco-
dynamic effects do not differ significantly between males 
and females, females tend to experience more gastrointest-
inal adverse reaction from their use than males.7
While there is not much known about how sex plays 
a role in post-discharge referrals, it is known that females 
with substance use disorders tend to experience greater 
financial issues, health difficulties, risk for recurrence of 
use,4 and mental health morbidity.3 It has been reported 
that women experience greater adverse symptoms after 
cessation of drug use, as well as worse effects on their 
mood and anxiety levels, which could help explain their 
increased risk of recurrence of use.5 The misuse of, and 
addiction to, opioids is a serious national crisis in the 
United States. Strategies to mitigate risk factors and pro-
vide data to continue the expansion of risk assessment 
tools are needed to help mitigate harmful use in the adult 
population.8
Additional research in sex factors in adults that affect 
harmful use of substances may allow us to find novel early 
sex-specific prevention programs, early intervention 
assessments, as well as risk assessment tools to hone our 
strategies.1 The influence of sex and gender on diagnosis, 
management, and even substance use prevention has been 
discussed previously in the literature.1,8 For instance, there 
are differences between the sexes in diagnoses related to 
opioid disbursement, response to opioids, opioid use dis-
order, pain, pain perception, and psychosocial factors.9 
Treatments for opioid use disorder generally focus on 
a uniform perspective that does not appropriately target 
these differences.9
United States’ trends demonstrate increased heroin 
use while nonmedical prescription opioid use is 
decreasing.10 Although recent studies have shown that 
both heroin and nonmedical prescription opioid use are 
more prevalent in men than women, women are increas-
ingly using heroin at a faster rate and lessening use of 
nonmedical prescription opioids at a slower rate than 
me.10 It has been found that substance use disorder 
progresses more rapidly in women than in men; this 
factor may contribute to the reason for women with 
harmful substance use becoming the quickest-growing 
population in the United States.11 Full exploration and 
knowledge of differences between males and females 
could lead to separate prevention and treatment pro-
grams, identification of medical and psychiatric comor-
bidities, and interventions for them, tailored by sex.11
This identification of observed sex differences among 
adult patients may provide us with the additional infor-
mation that will have implications for prevention, man-
agement, and treatment measures. Given broad access to 
electronic medical records, additional information on sex 
differences may be beneficial with multiple different 
applications; for example, using flags within the EMR 
system when a medication is prescribed to high-risk 
groups could alert a provider of precaution with prescrib-
ing certain medications (in particular if prescribing to 
those with risk factors like depression or anxiety disor-
ders). Substance use recovery may require treatment that 
expands the parameters of acute hospitalization; prior 
studies have shown that more women compared to men 
are discharged to non-detox-related facilities which may 
influence relapse in this population.2 Reviewing addi-
tional information on a simplistic level of patient differ-
entiation, such as sex, helps identify and target 
specialized risk-mitigating strategies to these groups.1
This study’s aim was to provide a review of bedside 
medical toxicologist managed, sex-specific poisonings in 
adults that present with harmful drug use/misuse.
Materials and Methods
The study data were obtained from the Toxicology 
Investigator’s Consortium (ToxIC) registry. The American 
College of Medical Toxicology (ACMT) produced the 
ToxIC registry in 2010 to compile data from medical toxicol-
ogists that were recorded in outpatient and inpatient settings. 
Medical toxicologists at numerous institutions nationally and 
internationally participate voluntarily by entering de-identified 
information into an online data collection form for all patients 
evaluated in person. The data collected include multiple demo-
graphic factors including sex, age and race; setting of consul-
tation; clinical presentation; provided interventions; poisoning 
type; and the reason for toxicological exposure.
The study protocol was reviewed by the lead author’s 
institutional review board (IRB) and due to the nature of 
the database, being deidentified and a part of national 
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registry, it was determined that it did not require IRB 
review. The following were obtained from the ToxIC 
registry: data regarding the reason for drug abuse/mis-
use, not including self-harm intent; single vs multiple 
exposures; type of exposure (acute, chronic or acute-on- 
chronic); agent of exposure; route of administration; 
clinical complications, including vital sign abnormalities, 
cardiovascular effects, neurological effects, life support 
and death; and treatment, including pharmacologic sup-
port, CPR, ECMO and intubation/ventilation. The ana-
lyses in this study included all cases in the ToxIC 
registry for patients age ≥19 and ≤65 with substance 
misuse or abuse between January 2010 and 
December 2016. Cases with missing data for age, or 
primary reason for encounter, or whose reason for inten-
tional encounter was not misuse/abuse were excluded 
from analysis. Descriptive statistics were used to assess 
study variables by sex. For purposes of this paper, the 
ToxIC registry term “drug abuse” was reported consis-
tent with newer nomenclature as “harmful substance 
use.”12
Results
The registry had 51,440 cases between 01/2010-12/2016. 
The sex distribution in the registry was similar with 25,871 
(50.3%) females and 25,569 (49.7%) males. Of the 51,440, 
a total of 34,255 were between the ages of 19–65, among 
which, 3426 were included for misuse/harmful use of 
a pharmaceutical or nonpharmaceutical substance 
(Figure 1, Flow Diagram). Table 1 depicts the demo-
graphics for the study sample according to sex. There 
were 2179 (64%) male subjects and 1229 (36%) female 
subjects, 24 (2%) of whom were pregnant. In regards to 
race, 1626 (55%) were reported as Caucasian and 653 
(22.1%) had an unknown/uncertain race.
Table 2 represents the harmful substance use/misuse 
information including reason for use, number of uses, 
agent of exposure and route of administration. Females 
were found to harmfully use/misuse pharmaceutical 
drugs more than nonpharmaceutical drugs: 806 (65.6%) 
of females used pharmaceutical drugs and 423 (34.4%) 
used nonpharmaceutical drugs. Of the females with 
reported pharmaceutical drug use, 312 (39.4%) were tak-
ing a prescribed medication more than intended and 167 
(21.1%) were taking the medication to elicit a pleasurable 
sensation. Males were found to use nonpharmaceutical 
drugs more frequently than pharmaceutical drugs: 1008 
(45.9%) of males used pharmaceutical drugs and 1189 
(54.1%) used nonpharmaceutical drugs.
Regarding the agent of exposure, opioids were the 
most commonly identified drugs among the entire sample: 
784 (24.2%) of the cases reported opioids as the agent of 
exposure. Of the total of female and male participants, 282 
(23.9%) females and 502 (24.3%) males were reported 
with opioids as agent of exposure. Sex differences were 
observed for other agents of exposure. Analgesics were 
used by females (N= 215, 18.2%) and males (N=137, 
6.6%). Sedative hypnotics were used by females (N=165, 
14%) and males (N=160, 7.8%). Psychoactive agents were 
used by males (N=325, 15.8%) and females (N=67, 5.7%). 
Sympathomimetics were used by males (N=381, 18.5%) 
and females (N=151, 12.8%).
The majority of both male and female participants, 
1712 (57.9%), utilized an oral route of administration. 
However, 312 (16.5%) of males utilized inhalation, vs 73 
(6.8%) of females inhaled their substance.
Table 3 shows the complications experienced by the 
participants, including systemic involvement (cardiovascu-
lar and nervous system), life support, pharmacologic sup-
port, CPR, ECMO and intubation/ventilation. Major vital 
sign abnormalities were reported, with 64.3% of females 
and 60.3% of males reported with none. Of the nervous 
system complications reported on, 39.9% of females and 
38.5% of males experienced coma. Pharmacological sup-
port data were provided and benzodiazepines were used as 
a treatment method for 49.0% of males in comparison to 
35.2% of females.
Discussion
Research on differences between sexes with respect to 
harmful substance use has been expanding in recent 
years. The 2016 National Survey on Drug Use and 
Health found differences in the percentages of illicit drug 
use by females and males in both 2015 and 2016, with 
males having a higher percentage of illicit drug use.13 
Currently, the opioid epidemic is on the forefront of public 
health concerns. Our study found opioids to be the most 
common agent involved in harmful substance use among 
both males and females, but there did not appear to be 
a difference between the sexes in regard to the percentage 
who used opioids compared to other agents of exposure. 
This finding is inconsistent with a previous study that 
found in the United States, opioid use disorder was 
reported at significantly higher rates among women.14 
However, this same study also discussed results similar 
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to our own. They discussed that women were more likely 
than men to use prescription drugs and were also more 
likely to have concurrent use of sedative-hypnotics.14 
Additionally, we found that a higher percentage of 
women used sedative-hypnotics and analgesics, when 
compared to the percentage of men that used these two 
agents. Men were found to have a higher rate of harmful 
use of psychoactive and sympathomimetic drugs.
Consistent with previous research, the results reported 
here demonstrate prominent disparities between the sexes 
with regards to pharmacological toxicities. For instance, 
a previous study found that females are more likely to start 
using drugs in order to self-medicate and reduce symptoms 
of mental disorders or illnesses.15 This is paralleled with 
our findings that females more often misused pharmaceu-
tical drugs by taking a prescribed medication at a higher 
dose than medically indicated as opposed to an attempt to 
elicit a pleasurable response. The clear differences noted in 
the results of our study can be expanded upon and 
employed clinically to further progress how we app n b 
roach harmful use.
By broadening the awareness within the medical com-
munity of the differences between sexes in regard to 
harmful substance use, more effort can be put toward 
customizing treatment options for patients. For example, 
exercise intervention for substance use disorder has gained 
popularity in recent years and some research has explored 
differences between sexes in response to this treatment.16 
Studies have found that long-term consistent aerobic exer-
cise can help reduce smoking risks in young males and 
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Pregnant 24 (2.0) –
Not Pregnant 1205 
(98.0)
–
Race N=2953 N=1048 N=1905
American Indian/ 
Alaska Native
32 (1.1) 15 (1.4) 17 (0.9)
Asian 28 (0.9) 9 (0.9) 19 (1.0)
Australian 
Aboriginal
1 (0.03) 0 1 (0.1)
Black/African 432 (14.6) 141 (13.5) 291 (15.3)
Caucasian 1626 (55.1) 593 (56.6) 1033 (54.2)
Native Hawaiian or 
Pacific Islander
4 (0.1) 2 (0.2) 2 (0.1)
Mixed 29 (1.0) 9 (0.9) 20 (1.0)
Other 147 (5.0) 39 (3.7) 108 (5.7)
Unknown/ 
Uncertain
653 (22.1) 240 (22.9) 413 (21.7)
Multiple Races 1 (0.03) 0 1 (0.01)
Hispanic/Latino N=2953 N=1048 N=1905
Yes 268 (9.1) 78 (7.4) 190 (10.0)
No 1982 (67.1) 705 (67.3) 1277 (67.0)
Unknown 703 (23.8) 265 (25.3) 438 (23.0)
Notes: The number in the top row for each variable (ie pregnancy status, race, 
Hispanic/Latino) represents the total for that variable, less missing data, and was the 
denominator used to calculate the percentages (shown in parenthesis) for all 
categories of that variable. If not present there was no missing data and total N/ 
denominator is presented in the top row of the table.
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Table 2 Harmful Drug Use/Misuse Information
Variables Entire Sample (N=3426) Female (N=1229) Male (N=2197)
Pharmaceutical Drug Abuse/Misuse 1814 (52.9) 806 (65.6) 1008 (45.9)
Reason for Pharmaceutical Drug Abuse/Misuse N=1786 N=792 N=994
Use of Rx med w/o Rx 73 (4.1) 28 (3.5) 45 (4.5)
Taking Rx med in higher than prescribed doses 592 (33.1) 312 (39.4) 280 (28.2)
Taking OTC med in higher than labeled doses 235 (13.2) 127 (16.0) 108 (10.9)
Taking excess doses or using other’s med 42 (2.4) 21 (2.7) 21 (2.1)
Taking med to elicit pleasurable sensation 539 (30.2) 167 (21.1) 372 (37.4)
Taking med to avoid withdrawal 19 (1.1) 6 (0.8) 13 (1.3)
Multiple reasons 286 (16.0) 131 (16.5) 155 (15.6)
Nonpharmaceutical Drug Abuse/Misuse 1612 (47.1) 423 (34.4) 1189 (54.1)
Reason for Nonpharmaceutical Drug Abuse/Misuse N=1527 N=398 N=1129
Taking substance to elicit pleasurable sensation 1480 (96.9) 384 (96.5) 1096 (97.1)
Taking substance to avoid withdrawal 47 (3.1) 14 (3.5) 33 (2.9)
Single or Multiple Exposure? N=3264 N=1182 N=2082
Single 2054 (62.9) 725 (61.3) 1329 (63.8)
Multiple 1210 (37.1) 457 (38.7) 753 (36.2)
Type of Exposure N=3342 N=1203 N=2139
Acute 2217 (66.3) 728 (60.5) 1489 (69.6)
Chronic 320 (9.6) 145 (12.1) 175 (8.2)
Acute-on-Chronic 702 (21.0) 298 (24.8) 404 (18.9)
Unknown 103 (3.1) 32 (2.7) 71 (3.3)
Agent #1 Class N=3241 N=1179 N=2062
Alcohol Ethanol 210 (6.5) 56 (4.7) 154 (7.5)
Alcohol Toxic 52 (1.6) 17 (1.4) 35 (1.7)
Amphetamine-like Hallucinogen 14 (0.4) 3 (0.3) 11 (0.5)
Analgesic 352 (10.9) 215 (18.2) 137 (6.6)
Anesthetic 0 0 0
Anticholinergic/Antihistamine 98 (3.0) 45 (3.8) 53 (2.6)
Anticoagulant 0 0 0
Anticonvulsant 33 (1.0) 14 (1.2) 19 (0.9)
Antidepressant 108 (3.3) 52 (4.4) 56 (2.7)
Antimicrobials 8 (0.2) 5 (0.4) 3 (0.1)
Antipsychotic 70 (2.2) 32 (2.7) 38 (1.8)
Cardiovascular 42 (1.3) 23 (2.0) 19 (0.9)
Caustic 1 (0.03) 0 1 (0.05)
Chelator 0 0 0
Chemotherapeutic and Immune 3 (0.1) 2 (0.2) 1 (0.05)
Cholinergic/Parasympathomimetic 0 0 0
Cough and Cold 69 (2.1) 9 (0.8) 60 (2.9)
Diabetic Med 9 (0.3) 2 (0.2) 7 (0.3)
Endocrine 4 (0.1) 1 (0.1) 3 (0.1)
Envenomation 0 0 0
Foreign Objects 0 0 0
Fungicide 0 0 0
Gases/Vapors/Irritants/Dust 5 (0.2) 2 (0.2) 3 (0.1)
GI 2 (0.1) 1 (0.1) 1 (0.05)
Herbals/Dietary Supps/Vitamins 19 (0.6) 2 (0.2) 17 (0.8)
Herbicide 0 0 0
(Continued)
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helps to increase recovery from methamphetamine depen-
dency for men.17 However, these results were not found to 
be true for female participants.18 Additionally, a body- 
mind exercise called Qigong has been utilized as 
a meditation therapy to diminish symptoms of withdrawal 
related to substance use. It was found that females may be 
more responsive to meditative therapy than males since 
females tend to suffer from more severe withdrawal 
symptoms.19 The differences between how males and 
females respond to exercise and meditation treatment for 
substance use disorder are simple examples of why treat-
ment is not “one size fits all.” The data obtained in this 
study can be utilized to direct future sex-specific harmful 
use screening techniques and treatments, as well as guide 
future research on the subject. Treatment for physical 
medical conditions is often tailored to the individual and 
it should be no different for harmful substance use. Further 
research should focus on how different treatments benefit 
males vs females in order to optimize outcomes and 
reduce withdrawal symptoms and recurrence of use.
The data forms used in the ToxIC database are com-
pleted on an elective basis at participating sites in the 
registry and are based on many factors. Examples for 
consideration could include availability or time- 
constraints for facilities, as well as severity and urgency 
of the cases, all of which may reflect a better or, more 
likely, a worse prognosis for cases excluded from the 
registry in comparison to included cases.
Therefore, cases in the ToxIC registry are not necessa-
rily inclusive of all the toxicological consults that are 
completed. Therefore, comparative and perhaps more 
meaningful statistical analyses were not considered for 
Table 2 (Continued). 
Variables Entire Sample (N=3426) Female (N=1229) Male (N=2197)
Household 10 (0.3) 4 (0.3) 6 (0.3)
Hydrocarbon 24 (0.7) 6 (0.5) 18 (0.9)
Insecticide 1 (0.03) 0 1 (0.05)
Lithium 13 (0.4) 5 (0.4) 8 (0.4)
Marine Toxin 0 0 0
Metals 3 (0.1) 2 (0.2) 1 (0.05)
Opioid 784 (24.2) 282 (23.9) 502 (24.3)
Other Non-pharmaceutical 4 (0.1) 2 (0.2) 2 (0.1)
Other Pharmaceutical 1 (0.03) 0 1 (0.05)
Parkinson’s Med 2 (0.1) 1 (0.1) 1 (0.05)
Photosensitizing Agents 0 0 0
Plants and Fungi 18 (0.6) 3 (0.3) 15 (0.7)
Psychoactive 392 (12.1) 67 (5.7) 325 (15.8)
Pulmonary 0 0 0
Rodenticide 1 (0.03) 0 1 (0.05)
Sed-Hypnotic/Muscle Relaxant 325 (10.0) 165 (14.0) 160 (7.8)
Sympathomimetic 532 (16.4) 151 (12.8) 381 (18.5)
WMD/NBC/Riot 0 0 0
Unknown Agent 32 (1.0) 10 (0.8) 22 (1.1)
Route of Administration N=2959 N=1067 N=1892
Oral 1712 (57.9) 723 (67.8) 989 (52.3)
Inhalation 385 (13.0) 73 (6.8) 312 (16.5)
Parenteral 263 (8.9) 80 (7.5) 183 (9.7)
Intranasal 124 (4.2) 31 (2.9) 93 (4.9)
Dermal 13 (0.4) 10 (0.9) 3 (0.2)
Unknown 428 (14.5) 140 (13.1) 288 (15.2)
Rectal 4 (0.1) 1 (0.1) 3 (0.2)
Other 30 (1.0) 9 (0.8) 21 (1.1)
Notes: The number in the top row for each variable (shown in bold font) represents the total for that variable, less missing data, and was the denominator used to calculate 
the percentages (shown in parenthesis) for all categories of that variable. If not present there was no missing data and total N/denominator is presented in the top row of the 
table.
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Table 3 Complications
Variables Entire Sample (N=3426) Female (N=1229) Male (N=2197)
Major Vital Sign Abnormalities N=2399 N=831 N=1568
Hypotension 122 (5.1) 58 (7.0) 64 (4.1)
Hypertension 59 (2.5) 30 (3.6) 29 (1.8)
Bradycardia 66 (2.8) 27 (3.2) 39 (2.5)
Tachycardia 308 (12.8) 88 (10.6) 220 (14.0)
Tachypnea 0 0 0
Bradypnea 146 (6.1) 41 (4.9) 105 (6.7)
Hyperthermia 6 (0.3) 0 6 (0.4)
Hypothermia 0 0 0
None 1479 (61.7) 534 (64.3) 945 (60.3)
Multiple Symptoms 213 (8.9) 53 (6.4) 160 (10.2)
Cardiovascular N=2173 N=764 N=1409
Ventricular dysrhythmias 39 (1.8) 15 (2.0) 24 (1.7)
Prolonged QT 106 (4.9) 45 (5.9) 61 (4.3)
Prolonged QRS 37 (1.7) 9 (1.2) 28 (2.0)
None 1975 (90.9) 688 (90.1) 1287 (91.3)
Multiple Symptoms 16 (0.7) 7 (0.9) 9 (0.6)
Nervous System N=2792 N=967 N=1825
Agitation 270 (9.7) 81 (8.4) 189 (10.4)
Delirium/psychosis 164 (5.9) 59 (6.1) 105 (5.8)
Coma 1088 (39.0) 386 (39.9) 702 (38.5)
Seizures 77 (2.8) 22 (2.3) 55 (3.0)
Hyperreflexia/clonus/tremor 60 (2.1) 20 (2.1) 40 (2.2)
EPS/dystonia/rigidity 13 (0.5) 9 (0.9) 4 (0.2)
None 393 (14.1) 162 (16.8) 231 (12.7)
Multiple symptoms 727 (26.0) 228 (23.6) 499 (27.3)
Death N=3178 N=1135 N=2043
Yes 47 (1.5) 20 (1.8) 27 (1.3)
No 3131 (98.5) 1115 (98.2) 2016 (98.7)
Life Support Withdrawn N=48 N=21 N=27
Yes 30 (62.5) 14 (66.7) 16 (59.3)
No 13 (27.1) 6 (28.6) 7 (25.9)
Unknown 5 (10.4) 1 (4.8) 4 (14.8)
Pharmacologic Support N=2067 N=716 N=1351
Vasopressors 68 (3.3) 27 (3.8) 41 (3.0)
Benzodiazepines 914 (44.2) 252 (35.2) 662 (49.0)
Opioids 25 (1.2) 9 (1.3) 16 (1.2)
Neuromuscular blockers 11 (0.5) 2 (0.3) 9 (0.7)
Glucose 27 (1.3) 12 (1.7) 15 (1.1)
Bronchodilators 10 (0.5) 7 (1.0) 3 (0.2)
Steroids 6 (0.3) 3 (0.4) 3 (0.2)
Anticonvulsants 0 0 0
Antiarrhythmics 8 (0.4) 3 (0.4) 5 (0.4)
None 821 (39.7) 342 (47.8) 479 (35.5)
Multiple treatments 177 (8.6) 59 (8.2) 118 (8.7)
CPR N=3426 N=1229 N=2197
Yes 43 (1.3) 15 (1.2) 28 (1.3)
No 3383 (98.7) 1214 (98.8) 2169 (98.7)
(Continued)
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our data. Readers must keep this in mind when considering 
the results. Incomplete, contradictory, or missing data form 
information resulted in the exclusion of many cases. 
Analyses were performed based only on the main agent 
considered responsible for the toxicological encounter. 
Thus, we could not evaluate the effects of drug interac-
tions or multiple drugs contributing to the whole toxicolo-
gical picture. Finally, the study of substance use varies 
over time and this dataset can only illustrate outcomes 
within our parameters from 2011 to 2016. The impact of 
these limitations on our study findings is not known.
Conclusion
We reported on characteristics of patient evaluated for harm-
ful substance use/misuse by toxicologists. There were sex- 
specific differences among patients in their reason for use, 
number of uses, agent of exposure and route of administra-
tion. Considering these differences in regards to manage-
ment and preventive approaches may be indicated.
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